Mena Vázquez, NataliaFernández Nebro, AntonioPego Reigosa, José MaríaGalindo, MaríaMelissa Anzola, AnaUriarte Isacelay, EstherOlivé Marqués, AlejandroAurrecoechea, ElenaFreire, MercedesTomero, EvaGarcía Villanueva, María JesúsStoye, ClaudiaSalas Heredia, EstebanBernal Vidal, Jose A.Salgado Pérez, EvaBlanco, RicardoNovoa, Francisco JavierIbáñez Barcelo, MónicaTorrente Segarra, VicenteNarváez García, Francisco JavierCalvet, JoanMoriano Morales, ClaraVázquez Rodríguez, Tomas RamonGarcía de la Peña, PalomaBohórquez, CristinaAndreu Sánchez, José LuisCobo-ibáñez, TatianaBonilla, GemaLozano Rivas, NuriaMontilla, CarlosToyos, Francisco JavierMarenco de la Fuente, José LuisExpósito, LorenaRuiz Lucea, María EstherVals, EliaManero Ruiz, JavierBernal Vidal, Jose A.Rua-Figueroa, Iñigo2020-11-042020-11-042020-08-01https://hdl.handle.net/2445/171742Objectives. This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. Methods. RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity. Results. Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]. Conclusion. Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies.8 p.application/pdfengcc by-nc (c) Mena Vázquez et al., 2020http://creativecommons.org/licenses/by-nc/3.0/es/Malalties autoimmunitàriesLupus eritematósAutoimmune diseasesLupus erythematosusinfo:eu-repo/semantics/article2020-11-03info:eu-repo/semantics/openAccess31808534